Literature DB >> 21653838

Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis.

Zhihua Ren1, Yan Wang, Duan Tao, David Liebenson, Thomas Liggett, Rajendra Goswami, Robert Clarke, Dusan Stefoski, Roumen Balabanov.   

Abstract

Interferon regulatory factor 1 (IRF-1) is a transcription factor that has been implicated in the pathogenesis of the human autoimmune demyelinating disease multiple sclerosis (MS) and in its animal model, experimental autoimmune encephalomyelitis (EAE). The goal of the present study was to directly examine the role of IRF-1 in oligodendrocyte injury and inflammatory demyelination. For the purpose of this study, we generated a transgenic mouse line (CNP/dnIRF-1) that overexpresses the dominant-negative form of IRF-1 (dnIRF1) specifically in oligodendrocytes. CNP/dnIRF-1 mice exhibited no phenotypic abnormalities but displayed suppressed IRF-1 signaling in oligodendrocytes. The major finding of our study was that the CNP/dnIRF-1 mice, compared with the wild-type mice, were protected against EAE, a phenomenon associated with significant reduction of inflammatory demyelination and with oligodendrocyte and axonal preservation. The observed protection was related to suppressed IRF-1 signaling and impaired expression of immune and proapoptotic genes in oligodendrocytes. No significant differences in the peripheral immune responses between the wild-type and the CNP/dnIRF-1 mice were identified throughout the experiments. This study indicates that IRF-1 plays a critical role in the pathogenesis of EAE by mediating oligodendrocyte response to inflammation and injury. It also suggests that oligodendrocytes are actively involved in the neuroimmune network, and that exploring oligodendrocyte-related pathogenic mechanisms, in addition to the conventional immune-based ones, may have important therapeutic implications in MS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653838      PMCID: PMC3770885          DOI: 10.1523/JNEUROSCI.1028-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  50 in total

Review 1.  IRF family of transcription factors as regulators of host defense.

Authors:  T Taniguchi; K Ogasawara; A Takaoka; N Tanaka
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival.

Authors:  Helmut Butzkueven; Jian-Guo Zhang; Merja Soilu-Hanninen; Hubertus Hochrein; Fiona Chionh; Kylie A Shipham; Ben Emery; Ann M Turnley; Steven Petratos; Matthias Ernst; Perry F Bartlett; Trevor J Kilpatrick
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

3.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

4.  Caspase-1 expression in multiple sclerosis plaques and cultured glial cells.

Authors:  Xue Ming; Weiping Li; Yasuhiro Maeda; Benjamin Blumberg; Sumul Raval; Stuart D Cook; Peter C Dowling
Journal:  J Neurol Sci       Date:  2002-05-15       Impact factor: 3.181

5.  IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination.

Authors:  Zhihua Ren; Yan Wang; David Liebenson; Thomas Liggett; Rajendra Goswami; Dusan Stefoski; Roumen Balabanov
Journal:  J Neuroimmunol       Date:  2011-01-22       Impact factor: 3.478

Review 6.  Acquired channelopathies in nerve injury and MS.

Authors:  S G Waxman
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

Review 7.  Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling.

Authors:  Chilakamarti V Ramana; M Pilar Gil; Robert D Schreiber; George R Stark
Journal:  Trends Immunol       Date:  2002-02       Impact factor: 16.687

Review 8.  The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease.

Authors:  K J Smith; W I McDonald
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

9.  De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis.

Authors:  Stephen Mark Tompkins; Josette Padilla; Mauro C Dal Canto; Jenny P-Y Ting; Luc Van Kaer; Stephen D Miller
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

10.  A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis.

Authors:  E S Huseby; D Liggitt; T Brabb; B Schnabel; C Ohlén; J Goverman
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

View more
  15 in total

1.  Cellular inhibitor of apoptosis 2 (cIAP2) restricts neuroinflammation during experimental autoimmune encephalomyelitis.

Authors:  Debolina D Biswas; Rebecca K Martin; LaShardai N Brown; Karli Mockenhaupt; Angela S Gupta; Michael J Surace; Anuj Tharakan; Jessie W Yester; Reetika Bhardwaj; Daniel H Conrad; Tomasz Kordula
Journal:  J Neuroinflammation       Date:  2022-06-19       Impact factor: 9.587

2.  Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica.

Authors:  Zhihua Ren; Yan Wang; Tao Duan; Jilpa Patel; Thomas Liggett; Eileah Loda; Sarang Brahma; Rajendra Goswami; Carrie Grouse; Richard Byrne; Dusan Stefoski; Adil Javed; Stephen D Miller; Roumen Balabanov
Journal:  J Immunol       Date:  2012-09-24       Impact factor: 5.422

3.  The Modulation of Interferon Regulatory Factor-1 via Caspase-1-Mediated Alveolar Macrophage Pyroptosis in Ventilator-Induced Lung Injury.

Authors:  Minhui Dai; Qian Li; Pinhua Pan
Journal:  Mediators Inflamm       Date:  2022-04-15       Impact factor: 4.529

Review 4.  The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Samuel S Duffy; Justin G Lees; Gila Moalem-Taylor
Journal:  Mult Scler Int       Date:  2014-10-12

5.  Inhibition of IRF5 hyperactivation protects from lupus onset and severity.

Authors:  Su Song; Saurav De; Victoria Nelson; Samin Chopra; Margaret LaPan; Kyle Kampta; Shan Sun; Mingzhu He; Cherrie D Thompson; Dan Li; Tiffany Shih; Natalie Tan; Yousef Al-Abed; Eugenio Capitle; Cynthia Aranow; Meggan Mackay; William L Clapp; Betsy J Barnes
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

6.  Design and screening of a glial cell-specific, cell penetrating peptide for therapeutic applications in multiple sclerosis.

Authors:  Corey Heffernan; Huseyin Sumer; Gilles J Guillemin; Ursula Manuelpillai; Paul J Verma
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

Review 7.  Molecular mechanisms of oligodendrocyte injury in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Jilpa Patel; Roumen Balabanov
Journal:  Int J Mol Sci       Date:  2012-08-23       Impact factor: 6.208

Review 8.  The unfolded protein response in multiple sclerosis.

Authors:  Sarrabeth Stone; Wensheng Lin
Journal:  Front Neurosci       Date:  2015-07-29       Impact factor: 4.677

Review 9.  Opposing Roles of Interferon-Gamma on Cells of the Central Nervous System in Autoimmune Neuroinflammation.

Authors:  Payton A Ottum; Gabriel Arellano; Lilian I Reyes; Mirentxu Iruretagoyena; Rodrigo Naves
Journal:  Front Immunol       Date:  2015-10-30       Impact factor: 7.561

10.  Interferon Regulatory Factor-1 Mediates Alveolar Macrophage Pyroptosis During LPS-Induced Acute Lung Injury in Mice.

Authors:  Dongdong Wu; Pinhua Pan; Xiaoli Su; Lemeng Zhang; Qingwu Qin; Hongyi Tan; Li Huang; Yuanyuan Li
Journal:  Shock       Date:  2016-09       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.